Taking everything into account, AZRX scores 2 out of 10 in our fundamental rating. AZRX was compared to 524 industry peers in the Biotechnology industry. While AZRX seems to be doing ok healthwise, there are quite some concerns on its profitability. AZRX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

AZRX had negative earnings in the past year.

1.2 Ratios

		Industry Rank	Sector Rank
ROA	-288.01%
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AZRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AZRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

AZRX has an Altman-Z score of -18.16. This is a bad value and indicates that AZRX is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for AZRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-18.16

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.33 indicates that AZRX should not have too much problems paying its short term obligations.
AZRX has a Quick Ratio of 1.33. This is a normal value and indicates that AZRX is financially healthy and should not expect problems in meeting its short term obligations.

		Industry Rank	Sector Rank
Current Ratio	1.33
Quick Ratio	1.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for AZRX have decreased strongly by -32.56% in the last year.

EPS 1Y (TTM)-32.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%5.88%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AZRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.05% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y52.24%

EPS Next 2Y28.65%

EPS Next 3Y20.55%

EPS Next 5Y11.05%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AZRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AZRX. No positive earnings are expected for the next year.